Known targets — ChEMBL curated mechanism
ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG
The experimentally established mechanism targets of Iodide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iodide SCHEMBL4189835 | 1.00 | CYP19A1 (0.32) | CYP19A1CYP11B2HIF1A | |
| Iodide SCHEMBL4189822 | 1.00 | CYP19A1 (0.32) | CYP19A1CYP11B2HIF1A | |
| Iodide SCHEMBL4189831 | 1.00 | CYP19A1 (0.32) | CYP19A1CYP11B2HIF1A | |
| Iodide SCHEMBL4355036 | 0.89 | CYP11B2 (0.36) | CYP19A1CYP11B2HIF1A | |
| Iodide SCHEMBL4355033 | 0.89 | CYP11B2 (0.36) | CYP19A1CYP11B2HIF1A | |
| Iodide SCHEMBL4355027 | 0.89 | CYP11B2 (0.36) | CYP19A1CYP11B2HIF1A | |
| Iodide SCHEMBL4355025 | 0.89 | CYP11B2 (0.36) | CYP19A1CYP11B2HIF1A | |
| SCHEMBL4192065 | 0.87 | CYP19A1 (0.35) | CYP19A1CYP11B2 | |
| SCHEMBL4192068 | 0.87 | CYP19A1 (0.35) | CYP19A1CYP11B2 | |
| SCHEMBL7823603 | 0.84 | CYP19A1 (0.36) | CYP19A1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090018342-A1 | NEW EPOTHIOLONE DERIVATIVES, PROCESS FOR THEIR PRODUCTION, AND THEIR PHARMACEUTICAL USE | KLAR ULRICH | 2009-01-15 | — | — | US | disclosed |
| US-7407975-B2 | Epothilone derivatives, method for producing same and their pharmaceutical use | BAYER SCHERING PHARMA AG (DE) | 2008-08-05 | — | — | US | disclosed |
| EP-1847540-A1 | Nouveaux dérivés d'épothilone, leur procédé de production et leur utilisation pharmaceutique | Bayer Schering Pharma Aktiengesellschaft (DE) | 2007-10-24 | — | — | EP | disclosed |
| EP-1005465-B1 | NEW EPOTHILONE DERIVATIVES, METHOD FOR PRODUCING SAME AND THEIR PHARMACEUTICAL USE | BAYER SCHERING PHARMA AG (DE) | 2007-07-25 | — | — | EP | disclosed |
| US-20030144523-A1 | EPOTHILONE DERIVATIVES, METHOD FOR PRODUCING SAME AND THEIR PHARMACEUTICAL USE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2003-07-31 | — | — | US | disclosed |
| EP-1005465-A2 | NEW EPOTHILONE DERIVATIVES, METHOD FOR PRODUCING SAME AND THEIR PHARMACEUTICAL USE | SCHERING AKTIENGESELLSCHAFT (DE) | 2000-06-07 | — | — | EP | disclosed |
| WO-1999007692-A2 | NEW EPOTHILONE DERIVATIVES, METHOD FOR PRODUCING SAME AND THEIR PHARMACEUTICAL USE | SCHERING AKTIENGESELLSCHAFT (DE) | 1999-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144523-A1 | EPOTHILONE DERIVATIVES, METHOD FOR PRODUCING SAME AND THEIR PHARMACEUTICAL USE | TUBB1, TUBA1C, TUBB4A | CYP19A1 300/4885CYP11B2 67/4885HIF1A 619/4885 |
| US-20090018342-A1 | NEW EPOTHIOLONE DERIVATIVES, PROCESS FOR THEIR PRODUCTION, AND THEIR PHARMACEUTICAL USE | TUBB4A, TUBA1B, TUBB | CYP19A1 89/4885CYP11B2 62/4885HIF1A 724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.